SIGA Technologies Target of Unusually Large Options Trading (NASDAQ:SIGA)

SIGA Technologies, Inc. (NASDAQ:SIGA) was the target of some unusual options trading activity on Wednesday. Traders acquired 1,200 call options on the company. This is an increase of approximately 1,438% compared to the average volume of 78 call options.

SIGA Technologies Trading Up 4.7 %

Shares of SIGA opened at $7.36 on Friday. The stock has a market cap of $525.50 million, a PE ratio of 6.13 and a beta of 0.89. SIGA Technologies has a 1 year low of $4.26 and a 1 year high of $12.83. The stock has a 50 day simple moving average of $6.99 and a 200-day simple moving average of $7.85.

SIGA Technologies (NASDAQ:SIGA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.02 earnings per share (EPS) for the quarter. SIGA Technologies had a return on equity of 49.06% and a net margin of 49.33%. The company had revenue of $10.01 million during the quarter. On average, sell-side analysts forecast that SIGA Technologies will post 1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On SIGA Technologies

Several institutional investors have recently added to or reduced their stakes in SIGA. Larson Financial Group LLC acquired a new stake in shares of SIGA Technologies during the third quarter worth approximately $30,000. DekaBank Deutsche Girozentrale acquired a new stake in SIGA Technologies during the 2nd quarter valued at $40,000. Bayesian Capital Management LP bought a new position in SIGA Technologies in the 1st quarter valued at $97,000. EP Wealth Advisors LLC acquired a new position in SIGA Technologies in the third quarter worth $82,000. Finally, Lazard Asset Management LLC acquired a new position in SIGA Technologies in the first quarter worth $105,000. 55.40% of the stock is owned by institutional investors.

About SIGA Technologies

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.